7.50
-0.11(-1.45%)
Currency In USD
| Previous Close | 7.61 |
| Open | 7.75 |
| Day High | 7.91 |
| Day Low | 7.39 |
| 52-Week High | 7.91 |
| 52-Week Low | 3.25 |
| Volume | 49,925 |
| Average Volume | 53,636 |
| Market Cap | 34.22M |
| PE | 2.55 |
| EPS | 2.94 |
| Moving Average 50 Days | 6.25 |
| Moving Average 200 Days | 6.1 |
| Change | -0.11 |
If you invested $1000 in Tenax Therapeutics, Inc. (TENX) 10 years ago, it would be worth $0.07 as of October 04, 2025 at a share price of $7.5. Whereas If you bought $1000 worth of Tenax Therapeutics, Inc. (TENX) shares 5 years ago, it would be worth $3.75 as of October 04, 2025 at a share price of $7.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
GlobeNewswire Inc.
Sep 16, 2025 11:00 AM GMT
Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimen
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
GlobeNewswire Inc.
Aug 28, 2025 11:00 AM GMT
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Mar 31, 2025 12:00 PM GMT
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary ther